MEN 11 A was described by Sipple 3 decades ago. Since then its autosomal dominant nature has been well established, usually presenting first with medullaty thyroid carcinoma (MTC), whose C cells produce calcitonin. Hyperparathyroidism and pheochromocytomas complete the triad. Most reports are among White Caucasian patients, especially in Europe. Our experience suggests that MEN II A is uncommon among Amcan Americans.
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For the past 22 years we have studied the lundred whose propositus (11-1) had MTC and whose mother (1-4) had the complete triad when recalled for medical check up. She had 12 children, 6 of which were diagnosed with MTC via elevated TCT levels. Seven out of 12 have undergone MTC removal and Hyperparathyroidism, while Pheochromocytomas have been identified in 3 out of 12. We wanted to established whether the same cysteine-rich region of exons 10-1 1 in the REToncogene were responsible, or whether this African American family had mutations in other exons, such as exon 15. By DNA sequencing of PCR products of the exon 10 and 1 1 regions of the RET gene in this kindred we were able to identify one previously unknown exon 10 mutation, an Asp-Asn mutation in codon 624. Most of the previously reported ret gene mutations associated with MEN I1 A are located in the amino acid 609-635 region, of the rer protein, includmg the mutation found in t h~s kindred. This extracellular region of the ret protein has been implicated in >90% of the studies of affected MEN I1 A families. MEN II A kindreds of African American origin might have unusual point mutations in the RET gene. This could have clinical relevance in screening young members of such families in order to prompt early therapeutic intervention. We acknowledge financial support from the NIH-RCMI-G12RR0305 1, NIH-MBRS S06GM08224 and the UPR School of Medicine.
Mumon analys~s of the fragile h~stldine tnad gene transcripts of pnmary tumors and unaffeded tissue usmg restriction nuclease fingerprinting and sequencing M Kaelblmg. Unlv. of M~ssissippi Medical Center, Jackson, MS.
The fragle hlst~dine tnad gene (FHIT) is a putatlve tumor suppressor gene USG) that spans the fragile chromosomal slte FRA3B at 3p14 2. To elucidate the role of this TSG in tumorigenes~s, the transcripts of 81 pnmary neoplasias of vanous tumor types and 10 benign tumors (leiomyoma uten) are being compared to those of constttutive tissue of the same pattents Total RNA is extracted from all samples and reverse-transcribed into cDNA. Exons 3-10 includmg the translated exons 5-9 are PCR-amplified The transcripts of each tumorlconst~tutive panel are first quantified and analyzed for size differences of > 50 bp in agarose gels. In one of 71 panels analyzed (1171). the tumor FHIT was underexpressed compared to actin while 6/71 yielded size differences wlthin the panel Next, the transcripts are compared by restriction The Fragile X syndrome (Fra-X) is characterized by mental retardatlo% macroorchidism and characteristic facial features, ~t is associated with the folate sensitive fragile site FRAXA at Xq27.3. The disease results from lack of expression of the FMRl gene and in the vast majority of cases the mutation is an expansion of a CGG lrinucleotide repeat localized in the 5' unttanslatcd region. In the National Institute of Pediatrics in Mexico City, there are many patients who are considered to have mental retardation of unknown cause (MRUC) after a multidisciplurary and exhaustive study. Some of them have clinical manifestations of Fra-X, although in 25 years, diagnosis has been confirmed with cytogenetic study in only five cases. This may be was due to a low frequency of Fra-X in ow population or to a misdiagnosis because molecular techniques were not previously available. The purpose of this paper was to establish the ffequency of Fra-X in a group of patients with MRUC by the molecular analysis of the FMR-I gene. Forty N a b i c patients of both sexes and their firstdegree relatives were included. The CGG trinucleotides were analyzed with PCR and Southem blot. Two of our patients had an expansion of the trinucleotides and it was interesting that one of them had not somatic alterations of the disease and mental retardation was the unique clinical manifestation of ?[a-X. We demonstrated by Southem blot that both mothers had a premutation &ad the brother of one of the index cases was also aEected. In our cases two patients had a family history and clinical manifestations which strongly suggested Fra-X but il was not col~oborated with this molecular study. Our results conilrm that the molecular analysis of the FMR-1 gene is necessary for a correct diagnosis of Fra-X and suggest that this disease is the cause of mental retardation in 5% of the patients considered to have MRUC in our population. Partial supported by CONACYT. A. Gondezdel Angel 90158. Alagille syndrome (AGS), a multisystem developmental disorder, is characterized by intrahepatic cholestasis and abnormalities of heart, eye and vertebrae and a characteristic facial appearance. The AGS phenotype has been associated with mutations in the Jagged1 gene (JAGI) which encodes a ligand in the Notch signalling pathway that is important in cell-fate determination in a number of tissues.
Molecular analysis of human
We report an Indian family with a two year old male proband presenting severe AGS with marked hypercholesterolemia while the mother presented only characteristic facial phenotype but normal liver and kidney function Mutation screening of all 26 exons of JAGl identified a 2841insA mutation in exon 21 (codon 824) in the patient. This mutation is predicted to cause a premature termination of translation of protein within the same codon. The mutated termination codon occurs within the EGF-like repeats domain of the JAGl protein This domain is highly conserved between Drosophila. rat and human. and is thought to be one of the regions which play a critical role in ligand-receptor interactions Direct sequencing of genomic DNA from the mother of the patient failed to reveal the presence of the 2841insA mutation As the 2841insA mutation abolishes a cutting site for Bsml, this restriction enzyme was also used to confirm the absence of this mutation in the mother. Our data show that that factors not attributable to the specific 2841insA mutation must play a role in determination of the subclinical AGS phenotype seen in the mother. 
